摘要
目的探究西黄胶囊结合甲苯磺酸索拉非尼片对化疗治疗的肝癌患者疗效、不良反应及肝功能影响。方法研究共计纳入97例肝癌患者,均由医院近3年收治,采取随机数字表法将患者分为对照组与观察组,对照组患者(48例)临床常规化疗治疗,观察组患者(49例)在对照组治疗基础上联合西黄胶囊及甲苯磺酸索拉非尼片治疗,比较两组患者临床治疗效果、治疗前后中医症状积分及癌痛评分(视觉模拟疼痛评分法,VAS)、治疗前后天冬氨酸氨基转氨酶(AST)、丙氨酸氨基转移酶(ALT)、总胆红素(TBIL)、白蛋白(ALB)等肝功能指标、血清血管内皮生长因子(VEGF)、骨桥蛋白(OPN)、缺氧诱导因子-1α(HIF-1α)、甲胎蛋白(AFP)水平变化、不良反应、生活质量(卡氏评分,KPS)、治疗满意率。结果观察组患者治疗有效率71.43%(35/49)高于对照组52.08%(25/48)(P<0.05);治疗前,两组患者中医症状积分、VAS评分、AST、ALT、TBIL、ALB等肝功能指标、血清VEGF、OPN、HIF-1α、AFP水平相当(P>0.05),治疗后各组患者中医症状积分、VAS评分、AST、ALT、TBIL、ALB等肝功能指标、血清VEGF、OPN、HIF-1α、AFP水平改善,观察组患者治疗后中医症状积分、VAS评分、AST、ALT、TBIL、ALB等肝功能指标、血清VEGF、OPN、HIF-1α、AFP水平优于对照组(P<0.05);观察组患者不良反应率低于对照组(P<0.05);观察组患者治疗后生活质量改善率91.84%(45/49)高于对照组72.92%(35/48)(P<0.05);观察组患者满意率93.88%(46/49)高于对照组77.08%(37/48)(P<0.05)。结论西黄胶囊结合甲苯磺酸索拉非尼片可提升肝癌患者治疗效果,改善患者症状及不良反应情况,提升患者肝功能,缓解癌痛,患者生活质量改善,满意率提升,值得推广以及应用。
Objective To explore the effect of Xihuang Capsule combined with Sorafenib Toluenesulfonic Acid Tablet on the efficacy, adverse reactions and liver function of liver cancer patients treated with chemotherapy. Methods In the study,97 patients with liver cancer treated in our hospital in nearly three years, according to a random number table method,were divided into control group(48 cases) and observation group(49 cases). The control group used clinical standard chemotherapy treatment and the observation group on the basis used Xihuang Capsule and Sorafenib Toluenesulfonic Acid Tablet. We compared two groups’ clinical therapeutic effect, symptom integral and pain score(visual analog pain score method, VAS), aspartate amino transaminase(AST), alanine aminotransferase(ALT), total bilirubin(TBIL), albumin(propagated) and other liver function indexes, serum levels of vascular endothelial growth factor(VEGF) and osteopontin(OPN), hypoxia inducing factor-1 alpha alpha(HIF-1α) and AFP, adverse reactions and quality of life(Carr’s score, KPS) and treatment satisfaction. Results The effective rate of treatment in the observation group 71.43%(45/49) was higher than that in the control group 52.08%(25/48)(P<0.05). Before treatment, TCM symptom score, VAS score, AST, ALT, TBIL, ALB and other liver function indicators, serum levels of VEGF, OPN, HIF-1α and AFP were similar in the two groups(P>0.05). After treatment, TCM symptom score, VAS score, AST, ALT, TBIL, ALB and other liver function indicators, serum levels of VEGF, OPN, HIF-1α and AFP were improved in the two groups. After treatment, TCM symptom score, VAS score, AST, ALT, TBIL, ALB and other liver function indicators, serum levels of VEGF, OPN, HIF-1α α and AFP in the observation group were better than those in the control group(P<0.05). The rate of adverse reaction in the observation group was lower than that in the control group(P<0.05). The quality of life improvement rate 91.84%(45/49) in the observation group was higher than that in the control group 72.92%(35/48)(P<0.05). The satisfaction rate of patients in the observation group 93.88%(46/49) was higher than that in the control group 77.08%(37/48)(P<0.05). Conclusion Xihuang Capsule combined with Sorafenib Toluenesulfonic Acid Tablet can improve the treatment effect of liver cancer patients, the symptoms and relieve adverse reactions of patients, improve the liver function of patients, relieve cancer pain and improve the quality of life of patients and the satisfaction rate. It is worthy of promotion and application.
作者
冯雪
李毅
陈谭昇
FENG Xue;LI Yi;CHEN Tansheng(Department of Infectious Diseases,Shengli Oilfield Central Hospital,Dongying 257034,Shandong,China)
出处
《中华中医药学刊》
CAS
北大核心
2020年第12期221-224,共4页
Chinese Archives of Traditional Chinese Medicine
基金
山东省医药卫生科技发展计划(2017WS856)。
关键词
肝癌
化疗
西黄胶囊
甲苯磺酸索拉非尼片
疗效
肝功能
不良反应
liver cancer
chemotherapy
Xihuang Capsule
Sorafenib Toluenesulfonic Acid Tablet
curative effect
liver function
adverse reactions
